BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

875 related articles for article (PubMed ID: 32271431)

  • 1. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
    Xiao XH; He SY
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
    Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
    Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-539 enhances chemosensitivity to cisplatin in non-small cell lung cancer by targeting DCLK1.
    Deng H; Qianqian G; Ting J; Aimin Y
    Biomed Pharmacother; 2018 Oct; 106():1072-1081. PubMed ID: 30119173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ELF1 suppresses autophagy to reduce cisplatin resistance via the miR-152-3p/NCAM1/ERK axis in lung cancer cells.
    Zhao L; Wu X; Zhang Z; Fang L; Yang B; Li Y
    Cancer Sci; 2023 Jun; 114(6):2650-2663. PubMed ID: 36846943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circ_PIP5K1A regulates cisplatin resistance and malignant progression in non-small cell lung cancer cells and xenograft murine model via depending on miR-493-5p/ROCK1 axis.
    Feng N; Guo Z; Wu X; Tian Y; Li Y; Geng Y; Yu Y
    Respir Res; 2021 Sep; 22(1):248. PubMed ID: 34537072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. circ_0007385 served as competing endogenous RNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells.
    Ye Y; Zhao L; Li Q; Xi C; Li Y; Li Z
    Thorac Cancer; 2020 Aug; 11(8):2196-2208. PubMed ID: 32602212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA SNHG1 contributes to the cisplatin resistance and progression of NSCLC via miR-330-5p/DCLK1 axis.
    Ge P; Cao L; Zheng M; Yao Y; Wang W; Chen X
    Exp Mol Pathol; 2021 Jun; 120():104633. PubMed ID: 33753110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis.
    Wang L; Shang X; Feng Q
    Cancer Biol Ther; 2019; 20(3):261-271. PubMed ID: 30481109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NORAD accelerates chemo-resistance of non-small-cell lung cancer via targeting at miR-129-1-3p/SOX4 axis.
    Huang Q; Xing S; Peng A; Yu Z
    Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31894841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-1 overexpression increases chemosensitivity of non-small cell lung cancer cells by inhibiting autophagy related 3-mediated autophagy.
    Hua L; Zhu G; Wei J
    Cell Biol Int; 2018 Sep; 42(9):1240-1249. PubMed ID: 29851226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-186-5p targeting SIX1 inhibits cisplatin resistance in non-small-cell lung cancer cells (NSCLCs).
    Liu X; Zhou X; Chen Y; Huang Y; He J; Luo H
    Neoplasma; 2020 Jan; 67(1):147-157. PubMed ID: 31686523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long non-coding RNA CASC2 enhances cisplatin sensitivity in oral squamous cell cancer cells by the miR-31-5p/KANK1 axis.
    Wang J; Jia J; Zhou L
    Neoplasma; 2020 Nov; 67(6):1279-1292. PubMed ID: 32787433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of CASC2/miR-21/PTEN pathway sensitizes cervical cancer to cisplatin.
    Feng Y; Zou W; Hu C; Li G; Zhou S; He Y; Ma F; Deng C; Sun L
    Arch Biochem Biophys; 2017 Jun; 623-624():20-30. PubMed ID: 28495512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of CASC2 contributes to cisplatin resistance in gastric cancer by sponging miR-19a.
    Li Y; Lv S; Ning H; Li K; Zhou X; Xv H; Wen H
    Biomed Pharmacother; 2018 Dec; 108():1775-1782. PubMed ID: 30372881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mir-126-5p Promotes Cisplatin Sensitivity of Non-Small-Cell Lung Cancer by Inhibiting ADAM9.
    Liu B; Wang R; Liu H
    Biomed Res Int; 2021; 2021():6622342. PubMed ID: 34055989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circ_0076305 regulates cisplatin resistance of non-small cell lung cancer via positively modulating STAT3 by sponging miR-296-5p.
    Dong Y; Xu T; Zhong S; Wang B; Zhang H; Wang X; Wang P; Li G; Yang S
    Life Sci; 2019 Dec; 239():116984. PubMed ID: 31647948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long non-coding RNA SNHG1 contributes to cisplatin resistance in non-small cell lung cancer by regulating miR-140-5p/Wnt/β-catenin pathway.
    Shi SL; Zhang ZH
    Neoplasma; 2019 Sep; 66(5):756-765. PubMed ID: 31288529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long non-coding RNA CASC2 targeting miR-18a suppresses glioblastoma cell growth, metastasis and EMT
    Wang J; Qin C; Zhong C; Wen Y; Ke S; Liao BO
    J Biosci; 2020; 45():. PubMed ID: 32975234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circ_0030998 Restrains Cisplatin Resistance Through Mediating miR-1323/PDCD4 Axis in Non-small Cell Lung Cancer.
    Zhu C; Jiang X; Xiao H; Guan J
    Biochem Genet; 2022 Dec; 60(6):2434-2454. PubMed ID: 35460386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-124 changes the sensitivity of lung cancer cells to cisplatin through targeting STAT3.
    Qi MM; Ge F; Chen XJ; Tang C; Ma J
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5242-5250. PubMed ID: 31298375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.